JP2022027762A5 - - Google Patents

Download PDF

Info

Publication number
JP2022027762A5
JP2022027762A5 JP2021183110A JP2021183110A JP2022027762A5 JP 2022027762 A5 JP2022027762 A5 JP 2022027762A5 JP 2021183110 A JP2021183110 A JP 2021183110A JP 2021183110 A JP2021183110 A JP 2021183110A JP 2022027762 A5 JP2022027762 A5 JP 2022027762A5
Authority
JP
Japan
Prior art keywords
cell
hinge
composition
car
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021183110A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022027762A (ja
Filing date
Publication date
Priority claimed from JP2018546725A external-priority patent/JP6976960B2/ja
Application filed filed Critical
Publication of JP2022027762A publication Critical patent/JP2022027762A/ja
Publication of JP2022027762A5 publication Critical patent/JP2022027762A5/ja
Priority to JP2024010098A priority Critical patent/JP2024028648A/ja
Priority to JP2025265629A priority patent/JP2026034683A/ja
Pending legal-status Critical Current

Links

JP2021183110A 2015-11-27 2021-11-10 遺伝子改変された細胞およびその使用 Pending JP2022027762A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024010098A JP2024028648A (ja) 2015-11-27 2024-01-26 遺伝子改変された細胞およびその使用
JP2025265629A JP2026034683A (ja) 2015-11-27 2025-12-18 遺伝子改変された細胞およびその使用

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AU2015904933 2015-11-27
AU2015904933A AU2015904933A0 (en) 2015-11-27 Genetically modified cells and uses thereof
AU2016901328A AU2016901328A0 (en) 2016-04-11 Genetically modified cells and uses thereof - III
AU2016901328 2016-04-11
JP2018546725A JP6976960B2 (ja) 2015-11-27 2016-11-23 遺伝子改変された細胞およびその使用
PCT/AU2016/051141 WO2017088012A1 (en) 2015-11-27 2016-11-23 Genetically modified cells and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018546725A Division JP6976960B2 (ja) 2015-11-27 2016-11-23 遺伝子改変された細胞およびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024010098A Division JP2024028648A (ja) 2015-11-27 2024-01-26 遺伝子改変された細胞およびその使用

Publications (2)

Publication Number Publication Date
JP2022027762A JP2022027762A (ja) 2022-02-14
JP2022027762A5 true JP2022027762A5 (https=) 2022-06-23

Family

ID=58762790

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018546725A Active JP6976960B2 (ja) 2015-11-27 2016-11-23 遺伝子改変された細胞およびその使用
JP2021183110A Pending JP2022027762A (ja) 2015-11-27 2021-11-10 遺伝子改変された細胞およびその使用
JP2024010098A Pending JP2024028648A (ja) 2015-11-27 2024-01-26 遺伝子改変された細胞およびその使用
JP2025265629A Pending JP2026034683A (ja) 2015-11-27 2025-12-18 遺伝子改変された細胞およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2018546725A Active JP6976960B2 (ja) 2015-11-27 2016-11-23 遺伝子改変された細胞およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024010098A Pending JP2024028648A (ja) 2015-11-27 2024-01-26 遺伝子改変された細胞およびその使用
JP2025265629A Pending JP2026034683A (ja) 2015-11-27 2025-12-18 遺伝子改変された細胞およびその使用

Country Status (11)

Country Link
US (3) US11400145B2 (https=)
EP (3) EP3380117B1 (https=)
JP (4) JP6976960B2 (https=)
CN (2) CN109152824B (https=)
AU (2) AU2016361451B2 (https=)
CA (1) CA3004120A1 (https=)
ES (2) ES2862907T3 (https=)
IL (2) IL296410A (https=)
MY (1) MY189819A (https=)
SG (2) SG11201803493UA (https=)
WO (1) WO2017088012A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4406604A3 (en) 2015-03-05 2024-10-23 Fred Hutchinson Cancer Center Immunomodulatory fusion proteins and uses thereof
AU2016361451B2 (en) * 2015-11-27 2024-01-25 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
KR102546839B1 (ko) 2016-08-03 2023-06-23 워싱턴 유니버시티 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집
US11525119B2 (en) 2016-09-06 2022-12-13 The Children's Medical Center Corporation Immune cells derived from induced pluripotent stem cell
CN119409836A (zh) 2017-03-17 2025-02-11 弗雷德哈钦森癌症中心 免疫调节融合蛋白及其用途
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
SG11201909331UA (en) * 2017-04-18 2019-11-28 Fujifilm Cellular Dynamics Inc Antigen-specific immune effector cells
US11771718B2 (en) * 2017-10-18 2023-10-03 Precigen, Inc. Polypeptide compositions comprising spacers
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CN109971721B (zh) * 2017-12-28 2023-10-31 上海细胞治疗研究院 自表达cd47抗体的间皮素特异性car-t细胞及其用途
CN109971716B (zh) * 2017-12-28 2023-08-01 上海细胞治疗研究院 自分泌cd47抗体的egfr特异性car-t细胞及其用途
WO2019157454A1 (en) 2018-02-11 2019-08-15 Memorial Sloan-Kettering Cancer Center Non-hla restricted t cell receptors and uses thereof
JP2021514360A (ja) * 2018-02-23 2021-06-10 カーサリクス プロプライエタリー リミテッド Ｔａｇ−７２を標的化するｔ細胞疾患処置
GB201804701D0 (en) * 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
GB201807945D0 (en) * 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Vector production
EP3801568A4 (en) * 2018-05-31 2022-03-16 Washington University GENOMIC-EDITED INVARIANT NATURAL KILLER T CELLS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNITIES
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
EP3830133A1 (en) 2018-08-01 2021-06-09 City of Hope Tag72 targeted chimeric antigen receptor modified t cells for treatment of tag72-positive tumors
CA3142947A1 (en) * 2019-06-12 2020-12-17 The Regents Of The University Of California Engineered off-the-shelf immune cells and methods of use thereof
CA3162755A1 (en) 2019-11-25 2021-06-03 Kyoto University T-cell master cell bank
US20230203125A1 (en) * 2020-05-22 2023-06-29 Chongqing Precision Biotech Co., Ltd. Fusion protein for reversing tumor microenvironment and use thereof
EP4161536A4 (en) * 2020-06-04 2024-08-14 Carisma Therapeutics Inc. Novel constructs for chimeric antigen receptors
WO2022061837A1 (en) * 2020-09-27 2022-03-31 Jiangsu Cell Tech Medical Research Institute Co., Ltd. Fibronectin extra domain b (edb) -specific car-t for cancer
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
BR112023018844A2 (pt) * 2021-04-07 2023-10-10 Century Therapeutics Inc Composições e métodos para geração de células t gama-delta de células-tronco pluripotentes induzidas
WO2022216624A1 (en) * 2021-04-07 2022-10-13 Century Therapeutics, Inc. Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells
WO2023110824A1 (en) * 2021-12-15 2023-06-22 Novo Nordisk A/S Novel integrin associated protein (iap)
CN114573710A (zh) * 2022-02-16 2022-06-03 南方医科大学珠江医院 一种靶向抗原同时外泌cd47抗体的免疫细胞及其应用
WO2024036214A2 (en) * 2022-08-10 2024-02-15 Jasper Therapeutics, Inc. Modified stem cell compositions and methods for use

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
EP0937095A4 (en) * 1996-10-25 1999-12-22 Cell Genesys Inc TARGETED CYTOLYSIS OF CANCER CELLS
US6908763B1 (en) 1997-08-22 2005-06-21 The Board Of Trustees Of The Leland Stanford Junior University Mammalian common lymphoid progenitor cell
US6331393B1 (en) 1999-05-14 2001-12-18 University Of Southern California Process for high-throughput DNA methylation analysis
US6761883B2 (en) 1999-06-29 2004-07-13 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
CA2375974C (en) 1999-06-29 2010-11-02 The Board Of Trustees Of The Leland Stanford Junior University Mammalian myeloid progenitor cell subsets
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2001275474A1 (en) 2000-06-12 2001-12-24 Akkadix Corporation Materials and methods for the control of nematodes
DE10130800B4 (de) 2001-06-22 2005-06-23 Epigenomics Ag Verfahren zum Nachweis von Cytosin-Methylierung mit hoher Sensitivität
US7446190B2 (en) * 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
AU2003273542A1 (en) 2002-05-31 2003-12-19 The Board Of Trustees Of The Leland Stanford Junior University Methods of identifying and isolating stem cells and cancer stem cells
US7592174B2 (en) 2002-05-31 2009-09-22 The Board Of Trustees Of The Leland Stanford Junior University Isolation of mesenchymal stem cells
EP1536688B1 (en) 2002-09-13 2011-12-28 The Board Of Trustees Of The Leland Stanford Junior University Mammalian megakaryocyte progenitor cell
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2005021594A2 (en) * 2003-08-29 2005-03-10 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of sdr-grafted humanized antibody cc49 and their use
JPWO2005035586A1 (ja) * 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
JP4970948B2 (ja) 2003-12-05 2012-07-11 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 癌幹細胞の同定、単離、および除去の方法
WO2005123909A2 (en) 2004-06-09 2005-12-29 The Board Of Trustees Of The Leland Stanford Junior University Isolation and characterization of muscle regenerating cells
US7641897B2 (en) 2004-11-23 2010-01-05 The Board Of Trustees Of The Leland Stanford Junior University Feeder layer and serum independent embryonic stem cells
US8691780B2 (en) 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
US8101728B2 (en) * 2005-04-28 2012-01-24 Danisco Us Inc. TAB molecules
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
US8377448B2 (en) 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
EP3424950A1 (en) 2006-10-06 2019-01-09 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Prevention of tissue ischemia, related methods and compositions
WO2008073316A2 (en) 2006-12-07 2008-06-19 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of acute myeloid leukemia stem cells
US7781179B2 (en) 2006-12-07 2010-08-24 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of transitional cell carcinoma stem cells
US8765390B2 (en) 2006-12-08 2014-07-01 The Board Of Trustees Of The Leland Stanford Junior University Identification and isolation of squamous carcinoma stem cells
EP3043181B1 (en) 2008-01-15 2020-04-08 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
US8450112B2 (en) 2008-04-09 2013-05-28 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
US8320687B2 (en) 2009-02-05 2012-11-27 The Board Of Trustees Of The Leland Stanford Junior University Universal lossy compression methods
WO2010141801A2 (en) * 2009-06-05 2010-12-09 Cellular Dynamics International, Inc. Reprogramming t cells and hematophietic cells
US9290577B2 (en) 2009-07-03 2016-03-22 Avipep Pty Limited Immuno-conjugates and methods for producing them
CA2771336C (en) 2009-09-15 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-cd47 therapy for hematologic cancers
WO2011041453A1 (en) 2009-09-29 2011-04-07 The Board Of Trustees Of The Leland Stanford Junior University Isolation and use of melanoma cancer stem cells
WO2011094538A1 (en) 2010-01-29 2011-08-04 The Board Of Trustees Of The Leland Stanford Junior University Depletion of teratoma-forming pluripotent stem cells
PT2569013T (pt) 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
ES2602743T3 (es) 2010-09-08 2017-02-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Receptores de antígenos quiméricos con una región bisagra optimizada
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140004174A (ko) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 암 치료를 위한 조성물 및 방법
MX2013011363A (es) * 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
RU2766608C2 (ru) 2012-04-11 2022-03-15 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
JP2015524255A (ja) * 2012-07-13 2015-08-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
HRP20230297T1 (hr) 2012-07-13 2023-05-12 The Trustees Of The University Of Pennsylvania UPRAVLJANJE TOKSIČNOŠĆU ZA ANTI-TUMORSKO DJELOVANJE CAR-a
US9045734B2 (en) 2012-07-31 2015-06-02 The Board Of Trustees Of The Leland Stanford Junior University Isolation and characterization of progenitor cells from mesothelium
JP6499079B2 (ja) * 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
BR112015013431A2 (pt) 2012-12-12 2017-11-14 Vasculox Inc anticorpos monoclonais ou respectivos fragmentos ligantes de antígenos, composição farmacêutica, e usos de anticorpo monoclonal ou respectivo fragmento ligante de antígenos
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CN105873952A (zh) * 2013-10-31 2016-08-17 弗莱德哈钦森癌症研究中心 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
ES2792849T3 (es) * 2014-02-10 2020-11-12 Univ Emory Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
US20180214527A1 (en) * 2015-03-26 2018-08-02 City Of Hope Bi-specific targeted chimeric antigen receptor t cells
KR20250141836A (ko) * 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
CN105331586B (zh) 2015-11-20 2020-09-15 上海细胞治疗研究院 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途
AU2016361451B2 (en) * 2015-11-27 2024-01-25 Cartherics Pty. Ltd. Genetically modified cells and uses thereof

Similar Documents

Publication Publication Date Title
JP2022027762A5 (https=)
JP2024028648A5 (https=)
JP2021177771A5 (https=)
US20220340676A1 (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
JP2023542348A5 (https=)
JP2025186319A5 (https=)
IL277079B1 (en) Cartyrin compositions and methods for use
JP2018504459A5 (https=)
JP2022109953A5 (https=)
JP2020108398A5 (https=)
JP2018535701A5 (https=)
JP2023530408A5 (https=)
JP2024023228A5 (https=)
RU2016124280A (ru) Клетка
JP2020529841A5 (https=)
IL275311B1 (en) Vcar preparations and methods of use
JP2018525033A5 (https=)
JP2023544890A5 (https=)
JP2018532407A5 (https=)
JP2022534680A5 (https=)
RS65343B1 (sr) Ćelija
JP2022501043A5 (https=)
JP2023518134A5 (https=)
JP2022542559A5 (https=)
JP2023512452A5 (https=)